ALKEM — Alkem Laboratories Balance Sheet
0.000.00%
- IN₹667.35bn
- IN₹639.84bn
- IN₹129.65bn
- 89
- 16
- 98
- 81
Annual balance sheet for Alkem Laboratories, fiscal year end - March 31st, INR millions except per share, conversion factor applied.
2021 March 31st | 2022 March 31st | 2023 March 31st | 2024 March 31st | 2025 March 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IAS | IAS | IAS | IAS | IAS |
| Status: | Final | Final | Final | Final | Final |
| Cash | |||||
| Cash and Equivalents | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 17,537 | 13,130 | 11,432 | 38,023 | 37,779 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 23,630 | 25,612 | 28,653 | 30,641 | 31,774 |
| Total Inventory | |||||
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 69,288 | 84,354 | 87,297 | 104,116 | 109,458 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 27,064 | 27,659 | 25,135 | 25,570 | 28,627 |
| Net Goodwill | |||||
| Net Intangible Assets | |||||
| Long Term Investments | |||||
| Long Term Notes Receivable | |||||
| Other Long Term Assets | |||||
| Total Assets | 115,193 | 140,692 | 137,566 | 155,749 | 176,911 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 36,041 | 48,053 | 37,072 | 39,946 | 39,650 |
| Long Term Debt | |||||
| Capital Lease Obligations | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Minority Interest | |||||
| Total Other Liabilities | |||||
| Total Funded Status | |||||
| Total Liabilities | 41,425 | 54,313 | 47,113 | 52,628 | 57,062 |
| Common Stock | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| ESOP Debt Guarantee | |||||
| Other Equity | |||||
| Total Equity | 73,767 | 86,379 | 90,453 | 103,121 | 119,849 |
| Total Liabilities & Shareholders' Equity | 115,193 | 140,692 | 137,566 | 155,749 | 176,911 |
| Total Common Shares Outstanding |